<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002162" GROUP_ID="AIRWAYS" ID="260499110515253351" MERGED_FROM="" MODIFIED="2011-05-11 18:30:38 +0200" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;CJC Technical edit 17/7/2001&lt;br&gt;1. Please add reviewer contributions.&lt;br&gt;2. I have run spell and grammar checking and tidied the references. I have changed the objective from role to efficacy of oral steroids. Also minor rewording of the association with colitis and the final implication for research.&lt;br&gt;3. This is now ready for Paul.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-05-11 17:26:15 +0100" NOTES_MODIFIED_BY="Emma J Welsh" REVIEW_NO="OCS-BRO" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2011-05-11 18:30:38 +0200" MODIFIED_BY="Emma Welsh">
<TITLE MODIFIED="2011-05-09 13:55:41 +0100" MODIFIED_BY="Toby  J Lasserson">Oral corticosteroids for bronchiectasis (stable and acute exacerbations)</TITLE>
<CONTACT MODIFIED="2011-05-11 18:30:38 +0200" MODIFIED_BY="Emma Welsh"><PERSON ID="8583" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Toby</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Lasserson</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Senior Editor</POSITION><EMAIL_1>tlasserson@cochrane.org</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Editorial Unit</DEPARTMENT><ORGANISATION>The Cochrane Collaboration</ORGANISATION><ADDRESS_1>13 Cavendish Square</ADDRESS_1><CITY>London</CITY><ZIP>W1G 0AN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7183 7503</PHONE_1><FAX_1>+44 20 7183 9163</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-05-11 18:30:38 +0200" MODIFIED_BY="Emma Welsh"><PERSON ID="8583" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Toby</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Lasserson</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Senior Editor</POSITION><EMAIL_1>tlasserson@cochrane.org</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Editorial Unit</DEPARTMENT><ORGANISATION>The Cochrane Collaboration</ORGANISATION><ADDRESS_1>13 Cavendish Square</ADDRESS_1><CITY>London</CITY><ZIP>W1G 0AN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7183 7503</PHONE_1><FAX_1>+44 20 7183 9163</FAX_1></ADDRESS></PERSON><PERSON ID="8574" ROLE="AUTHOR"><PREFIX>Ms.</PREFIX><FIRST_NAME>Kay</FIRST_NAME><LAST_NAME>Holt</LAST_NAME><POSITION>Nurse Practitioner</POSITION><EMAIL_1>kay.holt@btinternet.com</EMAIL_1><ADDRESS><DEPARTMENT>Cleveleys Group Practice</DEPARTMENT><ORGANISATION>Cleveleys Health Centre</ORGANISATION><CITY>Cleveleys</CITY><ZIP>FY5 3LF</ZIP><REGION>Lancs</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1253 853992</PHONE_1></ADDRESS></PERSON><PERSON ID="16873" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Stephen</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Milan</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>sjmilan@liverpool.ac.uk</EMAIL_1><EMAIL_2>milanstephen1@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7024110</PHONE_1><FAX_1>+44 151 7024335</FAX_1></ADDRESS></PERSON><PERSON ID="7552" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>Greenstone</LAST_NAME><POSITION>Consultant Chest Physician</POSITION><EMAIL_1>mike.greenstone@hey.nhs.uk</EMAIL_1><EMAIL_2>greenstone.mike@googlemail.com</EMAIL_2><ADDRESS><ORGANISATION>Castle Hill Hospital</ORGANISATION><CITY>Cottingham</CITY><ZIP>HU16 5JQ</ZIP><REGION>North Humberside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1482 875875</PHONE_1><FAX_1>+44 1482 876331</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-05-09 13:55:53 +0100" MODIFIED_BY="Toby  J Lasserson" NOTES="&lt;p&gt;Minor update: 21/05/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 21/05/07&lt;/p&gt;" NOTES_MODIFIED="2011-05-09 13:55:53 +0100" NOTES_MODIFIED_BY="Toby  J Lasserson">
<UP_TO_DATE>
<DATE DAY="5" MONTH="5" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="5" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2011-05-09 14:01:32 +0100" MODIFIED_BY="Toby  J Lasserson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-05-09 14:01:32 +0100" MODIFIED_BY="Toby  J Lasserson">
<DATE DAY="5" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Literature searches re-run. No new studies were identified. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-05-09 14:00:57 +0100" MODIFIED_BY="Toby  J Lasserson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-09 14:00:57 +0100" MODIFIED_BY="Toby  J Lasserson">
<DATE DAY="15" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="1" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Garfield Weston Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-05-11 17:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<SUMMARY MODIFIED="2011-05-09 13:58:18 +0100" MODIFIED_BY="Toby  J Lasserson">
<TITLE MODIFIED="2011-05-09 13:56:11 +0100" MODIFIED_BY="Toby  J Lasserson">Oral corticosteroids for bronchiectasis (stable and acute exacerbations)</TITLE>
<SUMMARY_BODY MODIFIED="2011-05-09 13:58:18 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>Bronchiectasis is a chronic respiratory disease. People with the condition experience difficulty in clearing mucus from their lungs, leaving them prone to infections. Oral steroids have a place in the management of acute and severe asthma. In bronchiectasis, inhaled steroids have small benefits but there is no evidence for or against the use of oral steroids for this condition.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-05-09 13:55:59 +0100" MODIFIED_BY="Toby  J Lasserson">
<ABS_BACKGROUND>
<P>Inflammation plays a significant role in the pathophysiology of bronchiectasis. Two small studies have shown small benefits from inhaled corticosteroids and oral corticosteroids may be of benefit in bronchiectasis</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy of oral corticosteroids in acute and stable bronchiectasis</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-05-09 13:55:59 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>The Cochrane Airways Group Specialised Register was searched and bibliographies of retrieved papers were checked. Searches are current as of May 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Only randomised controlled trials were considered</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>No trials met the inclusion criteria for the review. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No randomised controlled trials were identified</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There are no randomised trials upon which to base recommendations about the use of oral corticosteroids in acute or stable bronchiectasis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-05-11 17:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<BACKGROUND>
<P>Bronchiectasis is a chronic respiratory condition that can present at any age with chronic sputum production or recurrent respiratory infections. Recognised causes include congenital abnormalities, immunodeficiency, chronic inflammatory disorders and the sequelae of infection but most cases are idiopathic. Airflow obstruction is a common feature and may be sufficiently severe to cause respiratory failure and premature death. </P>
<P>Physiotherapy and antibiotics are the cornerstones of therapy and are considered mandatory in long term disease management where symptom control, treatment of exacerbations and the management of any associated respiratory failure are the usual clinical priorities. </P>
<P>Inflammation plays a significant role in the pathophysiology of bronchiectasis. In 45 children with cystic fibrosis (a specific form of bronchiectasis) long-term alternate day prednisolone showed significant benefits for the active treatment group in respect of height, weight, lung function, ESR and serum immunoglobulins after three years (<LINK REF="REF-Auerbach-1985" TYPE="REFERENCE">Auerbach 1985</LINK>). A substantial proportion of patients with bronchiectasis also have asthma (<LINK REF="REF-Murphy-1984" TYPE="REFERENCE">Murphy 1984</LINK>) and it might be anticipated that beneficial effects were mediated through improvement in the latter. Support for this comes from two small studies of inhaled corticosteroids in bronchiectasis that show small benefits in lung function and inflammatory markers in sputum (<LINK REF="STD-Elborn-1992" TYPE="STUDY">Elborn 1992</LINK>; <LINK REF="STD-Tsang-1997" TYPE="STUDY">Tsang 1997</LINK>). A systematic review has examined the role of inhaled steroids in bronchiectasis (<LINK REF="REF-Kolbe-1999" TYPE="REFERENCE">Kolbe 1999</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-05-09 13:56:28 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>The objectives of this systematic review were:</P>
<OL>
<LI>To determine the efficacy of oral corticosteroids in the treatment of acute exacerbation of bronchiectasis.</LI>
<LI>To determine the efficacy of long term oral corticosteroids in stable bronchiectasis.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2011-05-11 17:22:41 +0100" MODIFIED_BY="Emma J Welsh">
<SELECTION_CRITERIA MODIFIED="2011-05-09 13:59:06 +0100" MODIFIED_BY="Toby  J Lasserson">
<CRIT_STUDIES>
<P>Only randomised controlled trials were considered for this review. All double blind, single blind and open studies were considered for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All adults (and children) with bronchiectasis were included except those with cystic fibrosis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral corticosteroids administered either long term or in exacerbation. Comparisons were considered with placebo/no treatment or any other physical or drug treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-05-09 13:59:06 +0100" MODIFIED_BY="Toby  J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-05-09 13:58:52 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>Exacerbations: number and duration</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-05-09 13:59:06 +0100" MODIFIED_BY="Toby  J Lasserson">
<OL>
<LI>Symptoms: daily sputum volume, cough, dyspnoea, acute exacerbations</LI>
<LI>Health status (Quality of Life)</LI>
<LI>Change in lung function: e.g. forced expiratory volume in one second (FEV1)</LI>
<LI>Use of antibiotics</LI>
<LI>Decline in lung function</LI>
<LI>Morbidity: days off work, number and duration of hospital admissions</LI>
<LI>Mortality</LI>
<LI>Markers of systemic inflammation</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-05-11 17:22:41 +0100" MODIFIED_BY="Emma J Welsh">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and handsearching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as 'bronchiectasis' were searched using the following terms:</P>
<P>corticosteroid* or betamethasone* or cortisone* or deflazacort or hydrocortisone* or methylprednisolone* or prednisolone or dexamethasone* or triamcinolone*</P>
<P>Reference lists in retrieved papers were reviewed for additional references. The latest searches were carried out in May 2011.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-05-09 14:00:25 +0100" MODIFIED_BY="Toby  J Lasserson">
<STUDY_SELECTION MODIFIED="2011-05-09 13:59:30 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>The titles, abstracts and citations were reviewed to determine potential relevance for the full review. </P>
</STUDY_SELECTION>
<QUALITY_ASSESSMENT MODIFIED="2011-05-09 13:59:54 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>We plan to assess the risk of bias in each study according to the following domains:</P>
<OL>
<LI>Randomisation and allocation concealment</LI>
<LI>Blinding (participants, personnel and outcome assessors)</LI>
<LI>The handling of withdrawals</LI>
<LI>Selective outcome reporting</LI>
<LI>Other biases (such as carryover or adjustment within patient observation in crossover studies)</LI>
</OL>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-05-09 14:00:25 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>All included trials were to be analysed using Cochrane Review Manager software. Results were to be presented with 95% confidence intervals. Tests for heterogeneity would have been performed on the data.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-05-11 17:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<STUDY_DESCRIPTION MODIFIED="2011-05-11 17:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>A total of 71 abstracts were identified by electronic searches. Two reviewers (TL and KH) read through the searches and identified six abstracts, which were retrieved. None met the eligibility criteria for the review (See additional references and excluded studies). A further update search conducted in May 2011 did not yield any new studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No studies could be assessed</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>No data could be analysed</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Although two small studies demonstrate that high dose inhaled corticosteroids are effective in reducing inflammatory indices in sputum in severe non-CF bronchiectasis (<LINK REF="STD-Elborn-1992" TYPE="STUDY">Elborn 1992</LINK>, <LINK REF="STD-Tsang-1997" TYPE="STUDY">Tsang 1997</LINK>), the benefit of oral corticosteroids in acute or stable bronchiectasis is not proven. Nevertheless if inhaled steroids are beneficial then it would be reasonable to anticipate that oral steroids would have similar or even greater effects. Clinicians may feel that in mild cases of bronchiectasis the benefits are unknown and outweighed by the potential for side effects. In more severe cases particularly where there is coexisting airflow obstruction (characterised as asthma or COPD) then in some individuals short courses of oral corticosteroids may be helpful. Although bacterial infection is almost always found during exacerbations of bronchiectasis, there appears to be little risk of dissemination or septicaemia perhaps because antibiotics are invariably prescribed at the same time or because the organisms involved have a low propensity to cause bacteraemia. </P>
<P>Some people with bronchiectasis whose disease is associated with colitis or rheumatoid arthritis will require oral corticosteroids for the underlying inflammatory condition and patients with allergic bronchopulmonary aspergillosis and bronchiectasis may well require maintenance prednisolone plus booster courses for exacerbations of their underlying asthma. A wider group of patients with obvious asthma (which may coexist with bronchiectasis) will primarily be managed with inhaled corticosteroids but a small percentage with "difficult" asthma will require a maintenance dose of oral steroids. Hence there are a number of clinical settings where the use of systemic steroids is rational and, anecdotally, safe. Nevertheless it would be desirable if there was an evidence base on which to base these practices and to allow more rigorous quantification of the extent of any benefit and the potential risks.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>No relevant trials appear to have been published so this review concludes that there is no evidence for the benefit of oral corticosteroids in the treatment of acute exacerbations of bronchiectasis or stable bronchiectasis. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Randomised clinical trials of oral corticosteroids in bronchiectasis are required in order to gain a clear idea of the efficacy of this form of treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-15 11:39:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Many thanks to the editorial staff of the Cochrane Airways Group: Liz Arnold, Susan Hansen and Veronica Stewart.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-05-09 14:03:37 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>TJL: Study assessment, write-up</P>
<P>KH: Protocol development, study assessment; write-up. </P>
<P>SM: Guidance with methodological issues; write-up. </P>
<P>MG: Content expertise; protocol development; write-up. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-05-11 17:26:15 +0100" MODIFIED_BY="Emma J Welsh">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Elborn-1992" NAME="Elborn 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varghese G</AU>
<TI>Inhaled steroids in patients with bronchiectasis</TI>
<SO>Respiratory Medicine</SO>
<YR>1992</YR>
<VL>86</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsang-1997" NAME="Tsang 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Tsang KWT, Ho CS, HO PL, Lam WK, Ip M, Yven KY. Inhaled fluticasone is beneficial in stable idiopathic bronchiectasis. Eur. Respir. J. 1997. (10) Suppl 25, 3905 (abstract no 2497)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsang KWT, Ho CS, HO PL, Lam WK, Ip M, Yven KY</AU>
<TI>Inhaled fluticasone is beneficial in stable idiopathic bronchiectasis</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>Suppl 25</NO>
<PG>3905</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-05-11 17:26:15 +0100" MODIFIED_BY="Emma J Welsh">
<ADDITIONAL_REFERENCES MODIFIED="2011-05-11 17:26:15 +0100" MODIFIED_BY="Emma J Welsh">
<REFERENCE ID="REF-Auerbach-1985" MODIFIED="2008-08-15 11:39:07 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Auerbach 1985" TYPE="JOURNAL_ARTICLE">
<AU>Auerbach HS, William M, Kirkpatrick JA, Colten HR</AU>
<TI>Alternate-day prednisolone reduces morbidity and improves pulmonary function in cystic fibrosis</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>2</VL>
<PG>686-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolbe-1999" MODIFIED="2011-05-11 17:26:15 +0100" MODIFIED_BY="Emma J Welsh" NAME="Kolbe 1999" TYPE="COCHRANE_REVIEW">
<AU>Ram FSF, Wells A, Kolbe J</AU>
<TI>Inhaled steroids for bronchiectasis (Cochrane review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-05-11 17:26:15 +0100" MODIFIED_BY="Emma J Welsh">
<IDENTIFIER MODIFIED="2011-05-11 17:26:15 +0100" MODIFIED_BY="Emma J Welsh" TYPE="DOI" VALUE="10.1002/14651858.CD000996.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1984" MODIFIED="2008-08-15 11:39:07 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Murphy 1984" TYPE="JOURNAL_ARTICLE">
<AU>Murphy MB, Deen DJ, Fitzgerald MX</AU>
<TI>Atopy, immunological changes and respiratory function in bronchiectasis</TI>
<SO>Thorax</SO>
<YR>1984</YR>
<VL>31</VL>
<PG>179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-05-09 14:04:41 +0100" MODIFIED_BY="Toby  J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-05-09 14:04:41 +0100" MODIFIED_BY="Toby  J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-05-09 14:04:27 +0100" MODIFIED_BY="Toby  J Lasserson" STUDY_ID="STD-Elborn-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-09 14:04:27 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>Inhaled and not oral administration. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-09 14:04:41 +0100" MODIFIED_BY="Toby  J Lasserson" STUDY_ID="STD-Tsang-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-09 14:04:41 +0100" MODIFIED_BY="Toby  J Lasserson">
<P>Inhaled and not oral administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>